Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers
- PMID: 1965077
- DOI: 10.1016/0264-410x(90)90013-c
Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers
Abstract
The reactogenicity and immunogenicity of a formaldehyde-inactivated hepatitis A vaccine have been investigated. Three different dose levels of vaccine (180, 360 and 720 ELISA units) were administered to healthy volunteers according to a 0, 1, 2 and 12 month schedule. The vaccine was safe and well tolerated. Reactions observed following vaccination were essentially mild and were not dependent upon the quantity of antigen administered. All subjects had measurable titres of anti-HAV antibodies after the full vaccination course; the immune response to the vaccine was dose-related. Antibody titres in vaccinees at month 13 were between 60- and 190-fold higher than those observed in a group of subjects given anti-HAV immunoglobulin.
Similar articles
-
A trial of the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine.Isr J Med Sci. 1994 May-Jun;30(5-6):485-8. Isr J Med Sci. 1994. PMID: 8034508 Clinical Trial.
-
Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings.Vaccine. 1992;10 Suppl 1:S160-8. doi: 10.1016/0264-410x(92)90576-6. Vaccine. 1992. PMID: 1335652 Review.
-
Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine.Vaccine. 1992;10 Suppl 1:S132-4. doi: 10.1016/0264-410x(92)90567-4. Vaccine. 1992. PMID: 1335644 Clinical Trial.
-
Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence.J Med Virol. 1994 Dec;44(4):446-51. doi: 10.1002/jmv.1890440425. J Med Virol. 1994. PMID: 7897379 Clinical Trial.
-
[Vaccination against hepatitis A].Recenti Prog Med. 1992 Jun;83(6):313-20. Recenti Prog Med. 1992. PMID: 1323136 Review. Italian.
Cited by
-
Antigenic and immunogenic properties of recombinant hepatitis A virus 14S and 70S subviral particles.J Virol. 1993 Feb;67(2):1080-5. doi: 10.1128/JVI.67.2.1080-1085.1993. J Virol. 1993. PMID: 7678298 Free PMC article.
-
Analysis of serum hepatitis A virus antibody response in different courses of hepatitis A virus infection.J Gastroenterol. 1996 Dec;31(6):812-7. doi: 10.1007/BF02358607. J Gastroenterol. 1996. PMID: 9027644
-
The hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into viruslike particles.J Virol. 1991 Sep;65(9):5029-36. doi: 10.1128/JVI.65.9.5029-5036.1991. J Virol. 1991. PMID: 1651421 Free PMC article.
-
Clinical development of a new inactivated hepatitis A vaccine.Infection. 1996 Nov-Dec;24(6):447-58. doi: 10.1007/BF01713047. Infection. 1996. PMID: 9007593 Review. No abstract available.
-
Clinical trial with inactivated hepatitis A vaccine and recommendations for its use.BMJ. 1992 May 16;304(6837):1272-6. doi: 10.1136/bmj.304.6837.1272. BMJ. 1992. PMID: 1318765 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources